Exceptional Response to Immunotherapy-based Treatment in Compound EGFR-Mutated Oligometastatic Pulmonary Sarcomatoid Carcinoma: A Case Report

Pulmonary sarcomatoid carcinoma (PSC) is a rare and aggressive subtype of non–small cell lung cancer (NSCLC) with limited treatment options and poor prognosis. EGFR mutations generally respond to tyrosine kinase inhibitors (TKIs)-based targeted therapy but are typically associated with resistance to...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ayushi Gianchandani, Darshana Desai, Janani Sambath, Darshana Patil, Prashant Kumar, Shambhavi Singh, Chetan Madre, Ruturaj Deshpande, Anjali Parab, Niyati Shah, Darshit Shah, Pritam Kataria, Shrikanth Atluri, Marzi Mehta, Aditya Shreenivas, Rajan Datar, Razelle Kurzrock, Sewanti Limaye
Formato: Artigo
Lenguaje:Inglês
Publicado: Innovative Healthcare Institute 2025-08-01
Colección:Journal of Immunotherapy and Precision Oncology
Acceso en línea:https://jipo.org/doi/pdf/10.36401/JIPO-25-7
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares